NZ752750A - Stable aqueous capsaicin injectable formulations and medical uses thereof - Google Patents

Stable aqueous capsaicin injectable formulations and medical uses thereof

Info

Publication number
NZ752750A
NZ752750A NZ752750A NZ75275017A NZ752750A NZ 752750 A NZ752750 A NZ 752750A NZ 752750 A NZ752750 A NZ 752750A NZ 75275017 A NZ75275017 A NZ 75275017A NZ 752750 A NZ752750 A NZ 752750A
Authority
NZ
New Zealand
Prior art keywords
injectable formulations
stable aqueous
medical uses
aqueous capsaicin
capsaicin injectable
Prior art date
Application number
NZ752750A
Other languages
English (en)
Inventor
Drazen Ostovic
Gary Musso
Original Assignee
Centrexion Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centrexion Therapeutics Corp filed Critical Centrexion Therapeutics Corp
Publication of NZ752750A publication Critical patent/NZ752750A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ752750A 2016-11-02 2017-11-02 Stable aqueous capsaicin injectable formulations and medical uses thereof NZ752750A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416345P 2016-11-02 2016-11-02
PCT/US2017/059628 WO2018085476A1 (en) 2016-11-02 2017-11-02 Stable aqueous capsaicin injectable formulations and medical uses thereof

Publications (1)

Publication Number Publication Date
NZ752750A true NZ752750A (en) 2023-05-26

Family

ID=62077165

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ752750A NZ752750A (en) 2016-11-02 2017-11-02 Stable aqueous capsaicin injectable formulations and medical uses thereof

Country Status (11)

Country Link
US (7) US11000490B2 (enExample)
EP (1) EP3534961A4 (enExample)
JP (1) JP7100635B2 (enExample)
KR (1) KR102657458B1 (enExample)
CN (1) CN110035740B (enExample)
AU (1) AU2017353782B2 (enExample)
CA (1) CA3041121A1 (enExample)
IL (1) IL266279B2 (enExample)
MX (1) MX2019005202A (enExample)
NZ (1) NZ752750A (enExample)
WO (1) WO2018085476A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7100635B2 (ja) 2016-11-02 2022-07-13 セントレクシオン セラピューティクス コーポレイション 安定な水性カプサイシン注射製剤およびその医学的使用
IL272036B2 (en) 2017-07-20 2025-01-01 Centrexion Therapeutics Corp Methods and compositions for treating pain using capsaicin
JP2021534207A (ja) * 2018-08-24 2021-12-09 セントレクシオン セラピューティクス コーポレイション 膝関節痛の治療のためのカプサイシン連続投薬方法
CN114641485A (zh) 2020-04-05 2022-06-17 辉瑞大药厂 用于治疗covid-19的化合物和方法
CN113855626B (zh) * 2020-08-07 2023-03-24 北京泰德制药股份有限公司 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法
WO2023027670A2 (en) * 2021-08-23 2023-03-02 Tum Ekip Ilac Anonim Sirketi Lyophilized levosimendan compositions

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US5099030A (en) 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5431914A (en) 1992-04-17 1995-07-11 Adekunle; Michael Method of treating an internal condition by external application of capsaicin without the need for systemic absorption
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5985860A (en) 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
EP0646372B1 (de) 1993-09-30 1999-03-31 Medichemie Ag Capsaicin enthaltendes Arzneimittel zur Behandlung chronischer Rhinopathie
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
WO1998020867A1 (en) 1996-11-15 1998-05-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
US6060060A (en) 1997-01-31 2000-05-09 Bmb Patent Holding Corporation Analgesic compositions from sweet peppers and methods of use thereof
ATE219674T1 (de) 1997-03-13 2002-07-15 James N Campbell Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
JP2002514221A (ja) 1997-05-27 2002-05-14 アルゴス ファーマシューティカル コーポレーション カプサイシノイド及びその強化薬を含有する鎮痛薬組成物
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
WO2002076444A1 (en) 2001-03-22 2002-10-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Molecular neurochirurgerie for pain control administering locally capsaicin or resiniferatoxin
US20030104085A1 (en) 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
CA2493041C (en) 2002-07-19 2011-08-16 Dominik Meyer Injectable pharmaceutical composition for treating post-operative joint pain comprising an amide local anesthetic
JP2006513267A (ja) 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
US20040161481A1 (en) 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
EA012599B1 (ru) 2003-04-10 2009-10-30 Ньюроджескс, Инк. Способы и композиции для введения агонистов trpv1
EP2298287B1 (en) 2003-12-19 2018-04-11 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
MX2007006253A (es) 2004-11-24 2007-10-18 Anesiva Inc Formulacion de gel de capsaicinoide y usos para esta.
ES2355109T3 (es) 2004-12-22 2011-03-22 Mestex Ag Mezcla de un agonista de receptor de vainilloide con una sustancia inhibidora de la regeneración nerviosa, su utilización para la fabricación de un analgésico y procedimiento de aplicación de este fármaco.
WO2006069452A1 (de) 2004-12-28 2006-07-06 Mestex Ag Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
PL1838301T3 (pl) 2004-12-28 2015-08-31 Mestex Ag Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe
US20080160487A1 (en) 2006-12-29 2008-07-03 Fairfield Language Technologies Modularized computer-aided language learning method and system
US8222564B2 (en) 2008-02-13 2012-07-17 Tyco Healthcare Group, Lp Methods of altering surgical fiber
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
KR20110056516A (ko) 2008-09-12 2011-05-30 크리티컬 파머수티컬스 리미티드 점막 또는 피부를 통한 치료제의 흡수 개선
CN101507818B (zh) 2008-12-15 2010-11-10 中国人民武装警察部队医学院 辣椒碱β-环糊精包合物及包合物的脂质体及凝胶
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20130303495A1 (en) 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
CA2831146C (en) 2011-03-25 2019-06-04 Abbvie Inc. Trpv1 antagonists
BR112014005358A8 (pt) 2011-09-09 2017-10-03 Propella Therapeutics Inc Composições compreendendo agonista seletivo de trpv1 e seus usos
ES2644935T3 (es) 2012-04-18 2017-12-01 Mallinckrodt Llc Composiciones farmacéuticas de liberación inmediata con propiedades disuasorias del abuso
WO2013158814A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
EP2879660A1 (de) 2012-08-03 2015-06-10 Mestex AG Resiniferatoxin-lösung
JP6695140B2 (ja) 2012-11-12 2020-05-20 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー 水性カプサイシノイド配合物ならびにその製造法および使用法
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
GB201317756D0 (en) 2013-10-08 2013-11-20 Critical Pharmaceuticals Ltd New process
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20150133561A1 (en) 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
EP3096740B1 (en) 2014-01-24 2020-09-30 Sentiss Pharma Private Limited Pharmaceutical composition comprising brinzolamide
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
EA201692060A1 (ru) 2014-04-14 2017-02-28 Флекс Фарма, Инк. Активаторы ионного канала и способы их применения
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
CN105030760B (zh) 2014-04-24 2018-10-02 长弘生物科技股份有限公司 稳定医药组合物
WO2015198350A1 (en) 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
EA033046B1 (ru) 2014-06-25 2019-08-30 НУКАНА ПиЭлСи Состав, содержащий пролекарство гемцитабина
AU2015306063A1 (en) 2014-08-19 2017-04-13 Mandishora Israel MUZARI Capsaicinoids and uses thereof as medicaments
US20180311189A1 (en) 2014-11-13 2018-11-01 Centrexion Therapeutics Corporation Capsaicinoids for Use in Treating ACRAL Lick Granuloma
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
HK1253050A1 (zh) 2015-02-02 2019-06-06 英仕柏集团有限责任公司 稳定的富马酸二烷基酯组合物
MX2017015322A (es) 2015-05-29 2018-03-28 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de isotretinoin.
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
WO2017087803A1 (en) 2015-11-20 2017-05-26 Sorrento Therapeutics, Inc. Methods for pain treatment using resiniferatoxin
US9989978B2 (en) 2016-01-21 2018-06-05 Itt Manufacturing Enterprises Llc Natural gas pressure regulator having adjustable valve seat
AU2017210315A1 (en) 2016-01-22 2018-08-16 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of morton's neuroma pain
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
JP7100635B2 (ja) 2016-11-02 2022-07-13 セントレクシオン セラピューティクス コーポレイション 安定な水性カプサイシン注射製剤およびその医学的使用
WO2018217937A1 (en) 2017-05-24 2018-11-29 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia

Also Published As

Publication number Publication date
US10493047B2 (en) 2019-12-03
RU2019116788A3 (enExample) 2021-02-25
KR20190101368A (ko) 2019-08-30
US20210052522A1 (en) 2021-02-25
WO2018085476A1 (en) 2018-05-11
KR102657458B1 (ko) 2024-04-12
CN110035740A (zh) 2019-07-19
JP2019537589A (ja) 2019-12-26
US20190254996A1 (en) 2019-08-22
US20200093765A1 (en) 2020-03-26
AU2017353782A1 (en) 2019-05-16
AU2017353782B2 (en) 2022-06-02
US11344516B2 (en) 2022-05-31
EP3534961A1 (en) 2019-09-11
EP3534961A4 (en) 2020-05-27
US20200093766A1 (en) 2020-03-26
US10772853B2 (en) 2020-09-15
IL266279B2 (en) 2023-07-01
JP7100635B2 (ja) 2022-07-13
US11000490B2 (en) 2021-05-11
CN110035740B (zh) 2023-08-04
CA3041121A1 (en) 2018-05-11
US10765649B2 (en) 2020-09-08
RU2019116788A (ru) 2020-12-03
US20200046656A1 (en) 2020-02-13
US11992470B2 (en) 2024-05-28
IL266279A (en) 2019-06-30
IL266279B1 (en) 2023-03-01
MX2019005202A (es) 2019-10-14
US20220211649A1 (en) 2022-07-07
BR112019008239A2 (pt) 2019-07-16
US20240423931A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
NZ752750A (en) Stable aqueous capsaicin injectable formulations and medical uses thereof
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX2022000270A (es) Dispositivo para el suministro de una composicion para el cuidado de la piel.
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2021006035A (es) Formulaciones cannabinoides estables.
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
EP3808367A3 (en) Targeting aneurysm disease by modulating phagocytosis pathways
UA118261C2 (uk) Хімічні сполуки
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
BR112016027435A2 (pt) formulação inovadora de meloxicam
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
NZ728796A (en) Aqueous formulation comprising paracetamol and ibuprofen
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
MX395613B (es) COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER.
MX2020008275A (es) Metodos para tratar trastornos mitocondriales.
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112015000647A2 (pt) composições orais líquidas e pediátricas que contêm nepadutant

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2024 BY COMPUTER PACKAGES INC

Effective date: 20231017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2025 BY COMPUTER PACKAGES INC

Effective date: 20241017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2026 BY COMPUTER PACKAGES INC

Effective date: 20251017